Cancer Immunotherapy and Biomarkers has 2,101 eligible papers in the latest 30-day evidence window, up 104% from the prior window, with representative work spanning Immune checkpoint inhibitor-associated diabetes mellitus: an overlooked immune-related adverse event—two case reports and a literature review; Immune Checkpoint Inhibitors: efficacy, safety, and biomarkers - a systematic review; and Treatment and outcomes of immunotherapy related colitis and hepatitis- a multi-centre cohort study in the United Kingdom by the National Oncology Trainee Collaborative for Healthcare Research (NOTCH).
Cancer Immunotherapy and Biomarkers shows 2,101 eligible recent papers and 2,099 commentary-ready papers in the current 30-day window, compared with 1,032 eligible papers in the prior window. The strongest evidence comes from 1 visible topic cluster and 8 representative papers.
Cancer Immunotherapy and Biomarkers recorded 2,101 eligible papers in the latest 30-day window, compared with 1,032 in the prior 30-day window, making the current snapshot up 104% from the prior window.
2,101 recent vs 1,032 prior eligible papersCancer Immunotherapy and Biomarkers contributes 2,101 eligible recent papers, including 2,099 papers with abstracts available for commentary.
2,101 papers in the leading clusterThe representative set includes Immune checkpoint inhibitor-associated diabetes mellitus: an overlooked immune-related adverse event—two case reports and a literature review; Immune Checkpoint Inhibitors: efficacy, safety, and biomarkers - a systematic review; Treatment and outcomes of immunotherapy related colitis and hepatitis- a multi-centre cohort study in the United Kingdom by the National Oncology Trainee Collaborative for Healthcare Research (NOTCH); Severe immune checkpoint inhibitor-induced 3M syndrome: a case report; and Asymptomatic and Symptomatic Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Insights from a Japanese Registry. These papers anchor the page's claims and keep the brief tied to visible evidence.
8 representative papersCancer Immunotherapy and Biomarkers accounts for 2,101 eligible recent papers, including 2,099 commentary-ready papers in this evidence window.
2,101 recent eligible papersThe selected papers cover Immune checkpoint inhibitor-associated diabetes mellitus: an overlooked immune-related adverse event—two case reports and a literature review; Immune Checkpoint Inhibitors: efficacy, safety, and biomarkers - a systematic review; Treatment and outcomes of immunotherapy related colitis and hepatitis- a multi-centre cohort study in the United Kingdom by the National Oncology Trainee Collaborative for Healthcare Research (NOTCH); and Severe immune checkpoint inhibitor-induced 3M syndrome: a case report.
8 representative papersA recent paper from Frontiers in Immunology in the Cancer Immunotherapy and Biomarkers evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Frontiers in Oncology in the Cancer Immunotherapy and Biomarkers evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Supportive Care in Cancer in the Cancer Immunotherapy and Biomarkers evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Frontiers in Immunology in the Cancer Immunotherapy and Biomarkers evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from European Heart Journal Open in the Cancer Immunotherapy and Biomarkers evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Clinical Cancer Research in the Cancer Immunotherapy and Biomarkers evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Experimental and Therapeutic Medicine in the Cancer Immunotherapy and Biomarkers evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from International Journal of Molecular Sciences in the Cancer Immunotherapy and Biomarkers evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.